A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of two targeted therapies as a possible
treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation.
The drugs involved in this study are:
- Osimertinib (Tagrisso)
- Selumetinib